Scarica l'app Stockscreener
16.27
1.45%
-0.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Precedente Chiudi:
$16.51
Aprire:
$16.66
Volume 24 ore:
1.19M
Relative Volume:
0.76
Capitalizzazione di mercato:
$2.54B
Reddito:
$340.81M
Utile/perdita netta:
$-419.65M
Rapporto P/E:
-5.7088
EPS:
-2.85
Flusso di cassa netto:
$-402.10M
1 W Prestazione:
-3.56%
1M Prestazione:
-8.80%
6M Prestazione:
+9.19%
1 anno Prestazione:
-21.93%
Intervallo 1D:
$15.69
$16.68
Intervallo di 1 settimana:
$15.69
$16.91
Portata 52W:
$10.57
$24.34
Denali Therapeutics Inc Stock (DNLI) Company Profile
Nome
Denali Therapeutics Inc
Settore
Industria
Telefono
(650) 866-8547
Indirizzo
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Confronta DNLI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
16.27 | 2.58B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2025-01-07 | Iniziato | Robert W. Baird | Outperform |
| 2025-01-03 | Iniziato | William Blair | Outperform |
| 2024-12-16 | Aggiornamento | Stifel | Hold → Buy |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Iniziato | B. Riley Securities | Buy |
| 2023-01-30 | Iniziato | SVB Securities | Outperform |
| 2022-12-05 | Iniziato | Cowen | Outperform |
| 2022-11-02 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-11-02 | Iniziato | BofA Securities | Buy |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-09-21 | Iniziato | Oppenheimer | Outperform |
| 2021-09-01 | Iniziato | SMBC Nikko | Outperform |
| 2021-05-18 | Iniziato | UBS | Buy |
| 2021-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-02-24 | Iniziato | Jefferies | Buy |
| 2020-02-19 | Iniziato | Stifel | Hold |
| 2020-01-27 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-26 | Iniziato | Wedbush | Neutral |
| 2019-09-13 | Iniziato | Nomura | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Iniziato | Janney | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Iniziato | Goldman | Neutral |
| 2018-01-02 | Iniziato | JP Morgan | Overweight |
| 2018-01-02 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Hunter Syndrome Treatment Market is expected to reach US$ - openPR.com
Denali’s Hunter syndrome therapy shows promise in Phase 1/2 trial - Investing.com Nigeria
Understanding Momentum Shifts in (DNLI) - Stock Traders Daily
Denali Therapeutics stock holds Buy rating at Jefferies on FDA approval confidence - Investing.com Nigeria
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - The Manila Times
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - GlobeNewswire Inc.
Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500
3 Biotech Stocks With Major 2026 Catalysts - Nasdaq
Denali Therapeutics clears technical benchmark, hitting 80-plus RS rating - MSN
What drives Denali Therapeutics Inc 4DN stock priceIPO Market Watch & Free Expert Stock Watchlists - earlytimes.in
Denali Therapeutics Earnings Notes - Trefis
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
BTIG reiterates Denali Therapeutics (DNLI) buy recommendation - MSN
Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions - Yahoo Finance
How Investors May Respond To Denali Therapeutics (DNLI) $200 Million Equity Raise And FDA Voucher Talks - Yahoo Finance
Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? - Insider Monkey
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
What risks investors should watch in Denali Therapeutics Inc. stockWeekly Risk Report & Free Community Supported Trade Ideas - Улправда
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
Is Denali Therapeutics Inc. stock a good choice for value investorsWeekly Volume Report & Expert Curated Trade Setup Alerts - Улправда
Precision Trading with Denali Therapeutics Inc. (DNLI) Risk Zones - Stock Traders Daily
Analyst Downgrade: Will Denali Therapeutics Inc. stock reach all time highs in 2025Weekly Market Report & Daily Stock Trend Watchlist - Улправда
Is Denali Therapeutics Inc. stock positioned for digital transformation2025 Market Trends & Daily Volume Surge Signals - Улправда
What insider trading reveals about Denali Therapeutics Inc. stock2025 AllTime Highs & Fast Gain Swing Alerts - Улправда
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flowsQuarterly Trade Summary & Free Risk Controlled Daily Trade Plans - Улправда
What dividend safety score for Denali Therapeutics Inc. stockJuly 2025 Big Picture & High Accuracy Investment Signals - DonanımHaber
Is Denali Therapeutics Inc. (4DN) stock a good hedge against inflationEarnings Growth Summary & Low Risk High Win Rate Picks - DonanımHaber
Is Denali Therapeutics Inc. stock recession proof2025 Support & Resistance & Detailed Earnings Play Strategies - DonanımHaber
What Wall Street predicts for Denali Therapeutics Inc. stock priceEarnings Miss & AI Enhanced Trading Alerts - DonanımHaber
What catalysts could drive Denali Therapeutics Inc. stock higherFed Meeting & Technical Buy Zone Confirmations - Улправда
Does Denali Therapeutics' (DNLI) Discounted Equity Raise Reveal a New Phase in Its Risk Strategy? - simplywall.st
Revenue per share of Denali Therapeutics Inc. – DUS:4DN - TradingView — Track All Markets
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle - The Globe and Mail
Denali Therapeutics (DNLI) funds add $0.01 prefunded warrants in public offering - Stock Titan
Marex Group plc Takes $3.67 Million Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Camber Capital Management LP Has $5.60 Million Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Will Denali's Expanding Pipeline Deliver Breakthroughs In Neurodegenerative Medicine? - RTTNews
Wedbush Issues Pessimistic Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price - MarketBeat
Wedbush Maintains 'Outperform' Rating for DNLI, Lowers Price Tar - GuruFocus
Wedbush Trims Price Target on Denali Therapeutics to $30 From $31, Keeps Outperform Rating - marketscreener.com
Denali Therapeutics prices stock offering at $17.50 per share - MSN
Goodwin Advised Royalty Pharma In $275 Million Royalty Funding Agreement With Denali Therapeutics - Mondaq
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI) - Seeking Alpha
Denali Therapeutics (NASDAQ:DNLI) Shares Gap DownHere's What Happened - MarketBeat
Denali Therapeutics dips after pricing $200M equity offering - MSN
Denali Therapeutics Prices $200 Million Public Offering - marketscreener.com
Denali Therapeutics Inc Azioni (DNLI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Denali Therapeutics Inc Azioni (DNLI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schuth Alexander O. | COFO and Secretary |
Aug 12 '25 |
Sale |
13.58 |
2,937 |
39,884 |
242,346 |
| Ho Carole | Chief Medical Officer |
Aug 12 '25 |
Sale |
13.58 |
2,937 |
39,884 |
217,391 |
| Ho Carole | Chief Medical Officer |
Aug 13 '25 |
Sale |
14.64 |
806 |
11,800 |
216,585 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):